Trialjectory, a NYC-based, AI-powered decision-support platform for patients, health-care providers and pharma, raised $20m in a Series A funding.
The round was led by Insight Partners, with participation from new investor JAL Ventures and from existing investors Contour Venture Partners, Rho Capital and TIA Ventures. Scott Barclay, Managing Director of Insight Partners. Scott will join the Trialjectory board.
The company will use the funding to expand its operations and development efforts.
Led by Tzvia Bader, Co-Founder and CEO, Trialjectory is an artificial intelligence (AI)-powered decision-support platform for cancer patients to own their treatment journey by creating a personalized treatment plan that enhances physician point of care. The SaaS Optimizer platform delivers actionable insights that directly influence trial design, improve operational processes, and marketing communication strategies, while ensuring alignment with patients’ needs and expectations.
Between 2019 to the end of 2021, Trialjectory’s patient community has grown to over 50,000 registered members of which, more than 40% represent diverse ethnicities which are typically underserved patient populations.
FinSMEs
07/02/2022